Medicare Will Pay Less for Ozempic and Wegovy in 2027. The Price-Negotiation List Is Out.
Medicare will soon start paying lower prices for Novo Nordisk’s weight- loss drug Wegovy and its Type 2 diabetes treatment Ozempic, the federal agency that manages the program said Friday.The announcement confirms the long-anticipated inclusion of the blockbuster Novo medicines among 15 additional drugs whose prices Medicare will be allowed to negotiate with drugmakers this year.